Truveta research published in JAMA Network Open shows rapid uptake of early measles vaccination during Texas outbreak

by Ellie Lampton | Nov 14, 2025

Truveta’s analysis of early measles, mumps, and rubella (MMR) vaccinations among Texas infants published today in JAMA Network Open. The study reveals a sharp increase in early MMR vaccinations among infants in Texas during the state’s 2025 measles outbreak, aligning...

Truveta research published in Radiology Advances introduces new AI model to estimate body composition from chest radiographs

by Ellie Lampton | Oct 29, 2025

Truveta is proud to announce the publication of its latest peer-reviewed research in Radiology Advances: “XComposition: Multimodal Deep Learning Model to Measure Body Composition Using Chest Radiographs and Clinical Data.” This groundbreaking study demonstrates the...

Regulatory-grade device evidence reimagined with new precision data from Truveta

by Ellie Lampton | Sep 23, 2025

Unique device identifier data linked with ADT and chargemaster data give medical device manufacturers unmatched visibility into device use, safety, and outcomes—accelerating regulatory submissions, discovering safety signals faster, and speeding innovation that shapes...

New study reveals shift in pediatric obesity treatment following AAP guidelines

by Ellie Lampton | Jul 14, 2025

BELLEVUE, Wash.—July 14, 2025—A groundbreaking study published today in Pediatrics Open Science shows a notable increase in the use of medication to treat pediatric obesity in the United States following the 2023 release of comprehensive guidelines by the American...

A new era in cancer research: Truveta offers the most complete, representative, and timely real-world data on all cancers

by Ellie Lampton | May 8, 2025

BELLEVUE, Wash. – May 8, 2025 – Today, Truveta announced a new era in cancer research with more than 7 million oncology patient journeys spanning more than 100 cancer types, delivering an unprecedented breadth of regulatory grade data to support researchers in...